Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ra Pharmaceuticals, Inc. (RARX) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ra Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1481512.
Total stock buying since 2016: $132,247,045.
Total stock sales since 2016: $13,957,629.
Total stock option exercises since 2016: $794,210.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2020 | 0 | $0 | 36,358 | $1,678,506 | 31,785 | $177,993 |
| 2019 | 0 | $0 | 153,877 | $5,474,396 | 210,329 | $616,217 |
| 2018 | 7,658,065 | $71,200,007 | 0 | $0 | 0 | $0 |
| 2017 | 0 | $0 | 294,195 | $6,734,930 | 0 | $0 |
| 2016 | 4,695,926 | $61,047,038 | 5,369 | $69,797 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2020-03 | 0 | $0 | 12,883 | $579,767 | 10,595 | $59,331 |
| 2020-02 | 0 | $0 | 10,595 | $493,854 | 10,595 | $59,331 |
| 2020-01 | 0 | $0 | 12,880 | $604,885 | 10,595 | $59,331 |
| 2019-12 | 0 | $0 | 22,880 | $1,078,736 | 20,595 | $88,031 |
| 2019-11 | 0 | $0 | 20,595 | $961,130 | 20,595 | $88,031 |
| 2019-10 | 0 | $0 | 22,880 | $1,072,206 | 20,595 | $88,031 |
| 2019-09 | 0 | $0 | 20,595 | $521,722 | 20,595 | $88,031 |
| 2019-08 | 0 | $0 | 22,880 | $635,663 | 20,595 | $88,031 |
| 2019-07 | 0 | $0 | 20,595 | $680,471 | 20,595 | $88,031 |
| 2019-06 | 0 | $0 | 23,452 | $524,468 | 20,595 | $88,031 |
| 2019-04 | 0 | $0 | 0 | $0 | 15,329 | $0 |
| 2019-02 | 0 | $0 | 0 | $0 | 50,835 | $0 |
| 2018-12 | 2,658,065 | $41,200,007 | 0 | $0 | 0 | $0 |
| 2018-02 | 5,000,000 | $30,000,000 | 0 | $0 | 0 | $0 |
| 2017-06 | 0 | $0 | 99,603 | $2,206,303 | 0 | $0 |
| 2017-05 | 0 | $0 | 109,977 | $2,755,472 | 0 | $0 |
| 2017-03 | 0 | $0 | 7,778 | $162,661 | 0 | $0 |
| 2017-02 | 0 | $0 | 76,837 | $1,610,494 | 0 | $0 |
| 2016-10 | 4,695,926 | $61,047,038 | 5,369 | $69,797 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-03-17 | Ricardo Alonso (See Remarks) | Sale | 2,288 | 44.25 | 101,244 |
| 2020-03-16 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 45.16 | 478,523 |
| 2020-03-16 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2020-02-18 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 46.61 | 493,854 |
| 2020-02-18 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2020-01-17 | Ricardo Alonso (See Remarks) | Sale | 2,285 | 47.02 | 107,440 |
| 2020-01-15 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 46.95 | 497,445 |
| 2020-01-15 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-12-17 | Ricardo Alonso (See Remarks) | Sale | 2,285 | 47.08 | 107,568 |
| 2019-12-17 | Read Simon (Chief Scientific Officer) | Sale | 10,000 | 47.08 | 470,820 |
| 2019-12-17 | Read Simon (Chief Scientific Officer) | Option Ex | 10,000 | 2.87 | 28,700 |
| 2019-12-16 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 47.23 | 500,348 |
| 2019-12-16 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-11-15 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 46.66 | 494,320 |
| 2019-11-15 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-11-14 | Read Simon (Chief Scientific Officer) | Sale | 10,000 | 46.68 | 466,810 |
| 2019-11-14 | Read Simon (Chief Scientific Officer) | Option Ex | 10,000 | 2.87 | 28,700 |
| 2019-10-17 | Ricardo Alonso (See Remarks) | Sale | 2,285 | 46.70 | 106,709 |
| 2019-10-16 | Read Simon (Chief Scientific Officer) | Sale | 10,000 | 46.87 | 468,730 |
| 2019-10-16 | Read Simon (Chief Scientific Officer) | Option Ex | 10,000 | 2.87 | 28,700 |
| 2019-10-15 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 46.89 | 496,767 |
| 2019-10-15 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-09-16 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 25.26 | 267,672 |
| 2019-09-16 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-09-12 | Read Simon (Chief Scientific Officer) | Sale | 10,000 | 25.41 | 254,050 |
| 2019-09-12 | Read Simon (Chief Scientific Officer) | Option Ex | 10,000 | 2.87 | 28,700 |
| 2019-08-23 | Ricardo Alonso (See Remarks) | Sale | 2,285 | 27.89 | 63,740 |
| 2019-08-23 | Read Simon (Chief Scientific Officer) | Sale | 10,000 | 27.77 | 277,700 |
| 2019-08-23 | Read Simon (Chief Scientific Officer) | Option Ex | 10,000 | 2.87 | 28,700 |
| 2019-08-23 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 27.77 | 294,223 |
| 2019-08-23 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-07-17 | Read Simon (Chief Scientific Officer) | Sale | 10,000 | 32.95 | 329,480 |
| 2019-07-17 | Read Simon (Chief Scientific Officer) | Option Ex | 10,000 | 2.87 | 28,700 |
| 2019-07-15 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 33.13 | 350,991 |
| 2019-07-15 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-06-21 | Ricardo Alonso (See Remarks) | Sale | 2,857 | 23.73 | 67,782 |
| 2019-06-18 | Read Simon (Chief Scientific Officer) | Sale | 10,000 | 22.65 | 226,500 |
| 2019-06-18 | Read Simon (Chief Scientific Officer) | Option Ex | 10,000 | 2.87 | 28,700 |
| 2019-06-17 | Farzaneh-far Ramin (Chief Medical Officer) | Sale | 10,595 | 21.73 | 230,186 |
| 2019-06-17 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,595 | 5.60 | 59,331 |
| 2019-04-16 | King John C (Chief Commercial Officer) | Option Ex | 15,329 | .00 | 0 |
| 2019-02-01 | Read Simon (Chief Scientific Officer) | Option Ex | 9,167 | .00 | 0 |
| 2019-02-01 | Farzaneh-far Ramin (Chief Medical Officer) | Option Ex | 10,417 | .00 | 0 |
| 2019-02-01 | Treco Douglas A (President and CEO) | Option Ex | 20,834 | .00 | 0 |
| 2019-02-01 | Lubner David Charles (Executive V.P. & CFO) | Option Ex | 10,417 | .00 | 0 |
| 2018-12-14 | Shah Rajeev M. | Buy | 1,006,452 | 15.50 | 15,600,006 |
| 2018-12-14 | Sandell Scott D (10% Owner) | Buy | 645,161 | 15.50 | 9,999,995 |
| 2018-12-12 | Kolchinsky Peter | Buy | 1,006,452 | 15.50 | 15,600,006 |
| 2018-02-14 | Shah Rajeev M. | Buy | 2,500,000 | 6.00 | 15,000,000 |
| 2018-02-14 | Kolchinsky Peter | Buy | 2,500,000 | 6.00 | 15,000,000 |
| 2017-06-19 | Novartis Ag (10% Owner) | Sale | 3,220 | 22.02 | 70,897 |
| 2017-06-16 | Novartis Ag (10% Owner) | Sale | 53,200 | 21.25 | 1,130,234 |
| 2017-06-08 | Novartis Ag (10% Owner) | Sale | 700 | 22.00 | 15,400 |
| 2017-06-07 | Novartis Ag (10% Owner) | Sale | 4,840 | 22.11 | 106,997 |
| 2017-06-06 | Novartis Ag (10% Owner) | Sale | 7,274 | 22.98 | 167,163 |
| 2017-06-05 | Novartis Ag (10% Owner) | Sale | 4,780 | 23.11 | 110,489 |
| 2017-06-02 | Novartis Ag (10% Owner) | Sale | 14,867 | 23.47 | 348,943 |
| 2017-06-01 | Novartis Ag (10% Owner) | Sale | 10,722 | 23.89 | 256,180 |
| 2017-05-31 | Novartis Ag (10% Owner) | Sale | 35,539 | 23.94 | 850,910 |
| 2017-05-26 | Novartis Ag (10% Owner) | Sale | 5,300 | 25.14 | 133,268 |
| 2017-05-25 | Novartis Ag (10% Owner) | Sale | 53 | 25.00 | 1,325 |
| 2017-05-24 | Novartis Ag (10% Owner) | Sale | 17,451 | 25.00 | 436,362 |
| 2017-05-18 | Novartis Ag (10% Owner) | Sale | 9,019 | 25.50 | 229,966 |
| 2017-05-17 | Novartis Ag (10% Owner) | Sale | 22,534 | 25.51 | 574,909 |
| 2017-05-16 | Novartis Ag (10% Owner) | Sale | 20,081 | 26.33 | 528,732 |
| 2017-03-01 | Novartis Ag (10% Owner) | Sale | 7,778 | 20.91 | 162,661 |
| 2017-02-28 | Novartis Ag (10% Owner) | Sale | 7,847 | 20.86 | 163,672 |
| 2017-02-27 | Novartis Ag (10% Owner) | Sale | 57,844 | 20.96 | 1,212,294 |
| 2017-02-24 | Novartis Ag (10% Owner) | Sale | 5,398 | 20.93 | 113,001 |
| 2017-02-23 | Novartis Ag (10% Owner) | Sale | 4,999 | 21.04 | 105,158 |
| 2017-02-22 | Novartis Ag (10% Owner) | Sale | 749 | 21.86 | 16,369 |
| 2016-10-31 | Lettmann Jason (Director) | Buy | 393,923 | 13.00 | 5,120,999 |
| 2016-10-31 | Lettmann Jason (Director) | Sale | 340 | 13.00 | 4,420 |
| 2016-10-31 | Morgenthaler Management Partners Ix, Llc (10% Owner) | Buy | 263,538 | 13.00 | 3,425,994 |
| 2016-10-31 | Morgenthaler Management Partners Ix, Llc (10% Owner) | Sale | 340 | 13.00 | 4,420 |
| 2016-10-31 | Shah Rajeev M. (Director) | Buy | 161,538 | 13.00 | 2,099,994 |
| 2016-10-31 | Viswanathan Ravi (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Viswanathan Ravi (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Nea 13 Gp, Ltd (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Nea 13 Gp, Ltd (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Novo A/s (10% Owner) | Buy | 246,154 | 13.00 | 3,200,002 |
| 2016-10-31 | Kolchinsky Peter | Buy | 161,538 | 13.00 | 2,099,994 |
| 2016-10-31 | Weller Harry R (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Weller Harry R (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Baskett Forest (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Baskett Forest (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Kolluri Krishna Kittu (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Kolluri Krishna Kittu (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Sandell Scott D (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Sandell Scott D (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Kerins Patrick J (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Kerins Patrick J (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Mott David M (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Mott David M (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Barrett M James (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Barrett M James (10% Owner) | Sale | 435 | 13.00 | 5,655 |
| 2016-10-31 | Novartis Ag (10% Owner) | Buy | 84,615 | 13.00 | 1,099,995 |
| 2016-10-31 | Novartis Ag (10% Owner) | Sale | 339 | 13.00 | 4,407 |
| 2016-10-31 | Barris Peter J (10% Owner) | Buy | 338,462 | 13.00 | 4,400,006 |
| 2016-10-31 | Barris Peter J (10% Owner) | Sale | 435 | 13.00 | 5,655 |
Insider trading activities including stock purchases, stock sales, and option exercises of RARX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ra Pharmaceuticals, Inc. (symbol RARX, CIK number 1481512) see the Securities and Exchange Commission (SEC) website.